Medicare and Medicaid programs: hospital standard for potentially HIV infectious blood and blood products--HCFA. Final rule.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Medicare and Medicaid programs: hospital standard for potentially HIV infectious blood and blood products--HCFA. Final rule.

Fed Regist. 1996 Sep 9;61(175):47423-34. Unique Identifier : AIDSLINE AHA/96406121

Abstract: This final rule requires hospitals participating in the Medicare and Medicaid programs to take appropriate action when the hospitals learn that they have received whole blood, blood components (including recovered plasma), source plasma, and source leukocytes (hereafter referred to as blood or blood products) that are at increased risk of transmitting Human Immunodeficiency Virus (HIV) infection. If the hospital learns that it has received blood or blood products collected from a donor recently exposed to HIV, before the donor as a sufficient level of antibody to be detected by the screening test for antibody to HIV, the hospital must quarantine any blood or blood products remaining in inventory pending confirmation testing. If the presence of HIV is confirmed by more specific testing, the hospital must notify patients who received the blood or blood product. This final rule is intended to ensure that proper health and safety steps are taken to minimize further spread of HIV infection. A final rule published elsewhere in this Federal Register by the Food and Drug Administration applies the same requirements to entities furnishing transfusion services that do not participate in the Medicare and Medicaid programs and clarifies the responsibilities of blood establishments to identify and notify the transfusion service that received affected blood and blood products.

Keywords: Blood Component Transfusion/*STANDARDS Blood Donors Blood Transfusion/*STANDARDS Human HIV Antibodies/BLOOD HIV Infections/EPIDEMIOLOGY/*PREVENTION & CONTROL/TRANSMISSION Medicaid/LEGISLATION & JURISPRUD/*STANDARDS Medicare/LEGISLATION & JURISPRUD/*STANDARDS Risk Factors Risk Management/LEGISLATION & JURISPRUD/*STANDARDS United States/EPIDEMIOLOGY United States Food and Drug Administration United States Health Care Financing Administration JOURNAL ARTICLE
961230
M96C1514

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .